ARTROPATÍAS INFLAMATORIAS Y ARTRITIS INDUCIDAS POR MICROCRISTALES
University of Nottingham
Nottingham, Reino UnidoPublikationen in Zusammenarbeit mit Forschern von University of Nottingham (20)
2024
-
2023 EULAR recommendations on imaging in diagnosis and management of crystal-induced arthropathies in clinical practice
Annals of the Rheumatic Diseases, Vol. 83, Núm. 6, pp. 752-759
2023
-
The 2023 ACR/EULAR Classification Criteria for Calcium Pyrophosphate Deposition Disease
Arthritis and Rheumatology, Vol. 75, Núm. 10, pp. 1703-1713
-
The 2023 ACR/EULAR classification criteria for calcium pyrophosphate deposition disease
Annals of the Rheumatic Diseases, Vol. 82, Núm. 10, pp. 1248-1257
2022
-
Identifying Potential Classification Criteria for Calcium Pyrophosphate Deposition Disease: Item Generation and Item Reduction
Arthritis Care and Research, Vol. 74, Núm. 10, pp. 1649-1658
2020
-
2018 updated European League against Rheumatism evidence-based recommendations for the diagnosis of gout
Annals of the Rheumatic Diseases, Vol. 79, Núm. 1, pp. 31-38
2019
-
Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout
Annals of the Rheumatic Diseases, Vol. 78, Núm. 11, pp. 1592-1600
2017
-
2016 updated EULAR evidence-based recommendations for the management of gout
Annals of the Rheumatic Diseases, Vol. 76, Núm. 1, pp. 29-42
-
Treat-To-Target (T2T) recommendations for gout
Annals of the Rheumatic Diseases, Vol. 76, Núm. 4, pp. 632-638
2015
-
Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: A systematic analysis for the Global Burden of Disease Study 2013
The Lancet, Vol. 386, Núm. 10010, pp. 2287-2323
-
Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: A systematic analysis for the Global Burden of Disease Study 2013
The Lancet, Vol. 386, Núm. 9995, pp. 743-800
2014
-
Improving cardiovascular and renal outcomes in gout: What should we target?
Nature Reviews Rheumatology, Vol. 10, Núm. 11, pp. 654-661
-
Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): A large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia
BMJ Open, Vol. 4, Núm. 7
-
Up-titration of allopurinol in patients with gout
Seminars in Arthritis and Rheumatism, Vol. 44, Núm. 1, pp. 25-30
2012
-
Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: A systematic analysis for the Global Burden of Disease Study 2010
The Lancet, Vol. 380, Núm. 9859, pp. 2197-2223
-
Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: A systematic analysis for the Global Burden of Disease Study 2010
The Lancet, Vol. 380, Núm. 9859, pp. 2163-2196
2011
-
EULAR recommendations for calcium pyrophosphate deposition. Part II: Management
Annals of the Rheumatic Diseases, Vol. 70, Núm. 4, pp. 571-575
-
European league against rheumatism recommendations for calcium pyrophosphate deposition. Part I: Terminology and diagnosis
Annals of the Rheumatic Diseases, Vol. 70, Núm. 4, pp. 563-570
2010
-
International position paper on febuxostat
Clinical Rheumatology, Vol. 29, Núm. 8, pp. 835-840
2006
-
EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the standing committee for international clinical studies including therapeutics (ESCISIT)
Annals of the Rheumatic Diseases, Vol. 65, Núm. 10, pp. 1301-1311
-
EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)
Annals of the Rheumatic Diseases, Vol. 65, Núm. 10, pp. 1312-1324